<?xml version='1.0' encoding='utf-8'?>
<document id="25017487"><sentence text="The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study."><entity charOffset="24-34" id="DDI-PubMed.25017487.s1.e0" text="everolimus" /><entity charOffset="83-93" id="DDI-PubMed.25017487.s1.e1" text="tacrolimus" /><pair ddi="false" e1="DDI-PubMed.25017487.s1.e0" e2="DDI-PubMed.25017487.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25017487.s1.e0" e2="DDI-PubMed.25017487.s1.e1" /></sentence><sentence text="Pharmacokinetic data regarding a drug-drug interaction between everolimus and tacrolimus are sparse"><entity charOffset="63-73" id="DDI-PubMed.25017487.s2.e0" text="everolimus" /><entity charOffset="78-88" id="DDI-PubMed.25017487.s2.e1" text="tacrolimus" /><pair ddi="false" e1="DDI-PubMed.25017487.s2.e0" e2="DDI-PubMed.25017487.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25017487.s2.e0" e2="DDI-PubMed.25017487.s2.e1" /></sentence><sentence text="" /><sentence text="In a pharmacokinetic substudy of the randomized ASSET trial, 46 de novo kidney transplant patients receiving very low (1" /><sentence text="5-3 ng/mL) or low (4-7 ng/mL) tacrolimus exposure after month 3, both with everolimus and steroids, provided area under the curve (AUC) concentration profiles at day 5 and months 1, 3, and 12"><entity charOffset="30-40" id="DDI-PubMed.25017487.s5.e0" text="tacrolimus" /><entity charOffset="75-85" id="DDI-PubMed.25017487.s5.e1" text="everolimus" /><entity charOffset="90-98" id="DDI-PubMed.25017487.s5.e2" text="steroids" /><pair ddi="false" e1="DDI-PubMed.25017487.s5.e0" e2="DDI-PubMed.25017487.s5.e0" /><pair ddi="false" e1="DDI-PubMed.25017487.s5.e0" e2="DDI-PubMed.25017487.s5.e1" /><pair ddi="false" e1="DDI-PubMed.25017487.s5.e0" e2="DDI-PubMed.25017487.s5.e2" /><pair ddi="false" e1="DDI-PubMed.25017487.s5.e1" e2="DDI-PubMed.25017487.s5.e1" /><pair ddi="false" e1="DDI-PubMed.25017487.s5.e1" e2="DDI-PubMed.25017487.s5.e2" /></sentence><sentence text="" /><sentence text="At month 12, mean values for tacrolimus trough concentration (C0), peak concentration (Cmax), and AUC0-12 in the very low tacrolimus group were approximately half that in the low tacrolimus group, but everolimus dose, C0, Cmax, and AUC0-12 were virtually identical in both groups"><entity charOffset="29-39" id="DDI-PubMed.25017487.s7.e0" text="tacrolimus" /><entity charOffset="122-132" id="DDI-PubMed.25017487.s7.e1" text="tacrolimus" /><entity charOffset="179-189" id="DDI-PubMed.25017487.s7.e2" text="tacrolimus" /><entity charOffset="201-211" id="DDI-PubMed.25017487.s7.e3" text="everolimus" /><pair ddi="false" e1="DDI-PubMed.25017487.s7.e0" e2="DDI-PubMed.25017487.s7.e0" /><pair ddi="false" e1="DDI-PubMed.25017487.s7.e0" e2="DDI-PubMed.25017487.s7.e1" /><pair ddi="false" e1="DDI-PubMed.25017487.s7.e0" e2="DDI-PubMed.25017487.s7.e2" /><pair ddi="false" e1="DDI-PubMed.25017487.s7.e0" e2="DDI-PubMed.25017487.s7.e3" /><pair ddi="false" e1="DDI-PubMed.25017487.s7.e1" e2="DDI-PubMed.25017487.s7.e1" /><pair ddi="false" e1="DDI-PubMed.25017487.s7.e1" e2="DDI-PubMed.25017487.s7.e2" /><pair ddi="false" e1="DDI-PubMed.25017487.s7.e1" e2="DDI-PubMed.25017487.s7.e3" /><pair ddi="false" e1="DDI-PubMed.25017487.s7.e2" e2="DDI-PubMed.25017487.s7.e2" /><pair ddi="false" e1="DDI-PubMed.25017487.s7.e2" e2="DDI-PubMed.25017487.s7.e3" /></sentence><sentence text=" In a cross-study comparison with data at months 1 and 3 from the pharmacokinetic substudy of the A2307 trial, in which patients received cyclosporine, mean values for everolimus C0, Cmax and AUC0-12 were similar to those in the ASSET trial but the everolimus dose needed to achieve similar exposure was 1"><entity charOffset="138-150" id="DDI-PubMed.25017487.s8.e0" text="cyclosporine" /><entity charOffset="168-181" id="DDI-PubMed.25017487.s8.e1" text="everolimus C0" /><entity charOffset="249-259" id="DDI-PubMed.25017487.s8.e2" text="everolimus" /><pair ddi="false" e1="DDI-PubMed.25017487.s8.e0" e2="DDI-PubMed.25017487.s8.e0" /><pair ddi="false" e1="DDI-PubMed.25017487.s8.e0" e2="DDI-PubMed.25017487.s8.e1" /><pair ddi="false" e1="DDI-PubMed.25017487.s8.e0" e2="DDI-PubMed.25017487.s8.e2" /><pair ddi="false" e1="DDI-PubMed.25017487.s8.e1" e2="DDI-PubMed.25017487.s8.e1" /><pair ddi="false" e1="DDI-PubMed.25017487.s8.e1" e2="DDI-PubMed.25017487.s8.e2" /></sentence><sentence text="5- to 2-fold higher with concomitant tacrolimus versus cyclosporine"><entity charOffset="55-67" id="DDI-PubMed.25017487.s9.e0" text="cyclosporine" /></sentence><sentence text="" /><sentence text="Everolimus exposure is unaffected when tacrolimus exposure is down-titrated within the trough concentration range of 1"><entity charOffset="39-49" id="DDI-PubMed.25017487.s11.e0" text="tacrolimus" /></sentence><sentence text="5-7 ng/mL" /><sentence text=" Higher doses of everolimus are needed to achieve a given exposure when combined with tacrolimus versus cyclosporine"><entity charOffset="17-27" id="DDI-PubMed.25017487.s13.e0" text="everolimus" /><entity charOffset="86-96" id="DDI-PubMed.25017487.s13.e1" text="tacrolimus" /><entity charOffset="104-116" id="DDI-PubMed.25017487.s13.e2" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.25017487.s13.e0" e2="DDI-PubMed.25017487.s13.e0" /><pair ddi="false" e1="DDI-PubMed.25017487.s13.e0" e2="DDI-PubMed.25017487.s13.e1" /><pair ddi="false" e1="DDI-PubMed.25017487.s13.e0" e2="DDI-PubMed.25017487.s13.e2" /><pair ddi="false" e1="DDI-PubMed.25017487.s13.e1" e2="DDI-PubMed.25017487.s13.e1" /><pair ddi="false" e1="DDI-PubMed.25017487.s13.e1" e2="DDI-PubMed.25017487.s13.e2" /></sentence><sentence text="" /></document>